Co-Founder Ugur Sahin's Medine GmbH Files to Sell $89M in BioNTech ADSs
BNTX sits 31% above its 52-week low of $79.52.
Summary
Medine GmbH, affiliated with co-founder Ugur Sahin, filed a Form 144 to sell 858,209 BioNTech ADSs worth about $89.1 million, shortly after Sahin stepped down as CEO.
Key Events · Ownership and Investor Activity · BNTX
-
Co-Founder Affiliate Files $89M Sale
Medine GmbH, an entity affiliated with co-founder Ugur Sahin, filed a Form 144 to sell 858,209 ADSs with an approximate market value of $89.1 million.
-
Shares From Option Exercises
The shares were acquired via stock option exercises on November 21, 2022 (856,186 shares) and August 9, 2024 (2,023 shares).
-
Follows CEO Departure
The sale intent comes roughly one month after Sahin stepped down as CEO on August 3, 2026, to start a new company.
-
Negative News Backdrop
BioNTech recently reported a €821 million Q2 net loss, cut 2026 revenue guidance to €2B–€2.3B, and terminated a Phase 2 colorectal cancer trial.
Analysis · BNTX · Life Sciences
A Form 144 filed by Medine GmbH, an entity affiliated with co-founder Ugur Sahin, discloses plans to sell 858,209 American Depositary Shares worth approximately $89.1 million. The shares stem from stock option exercises in 2022 and 2024. This sale intent surfaces just weeks after Sahin stepped down as CEO on August 3, 2026, and amid a wave of negative news for BioNTech, including a wider-than-expected Q2 loss, a 20% cut to 2026 revenue guidance, and the termination of a Phase 2 colorectal cancer trial. The combination of a departing co-founder's affiliated entity selling a large block of shares against this backdrop is a notable negative signal for investor sentiment.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $104.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.1B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.